NCT07786571Withdrawn
Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency
A Prospective, Randomized, Active-Controlled, Multicenter Clinical Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This study aims to evaluate whether dorzagliatin can improve glycemic homeostasis in patients with type 2 diabetes mellitus (T2DM) complicated by chronic renal insufficiency, and to compare the efficacy of dorzagliatin with linagliptin in improving glycemic control in patients with T2DM and moderate to severe chronic renal insufficiency (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m²). This is a prospective, randomized, active-controlled, multicenter clinical study planned to enroll 206 eligible patients. After successful screening, patients will enter a 2-week run-in period consisting of diet and exercise control together with continuous glucose monitoring (CGM). Eligible patients will then be randomized to receive dorzagliatin 75 mg twice daily (BID) or linagliptin 5 mg once daily (QD) on top of background antihyperglycemic therapy. Basal insulin therapy will be standardized to insulin glargine U300 after treatment initiation. The treatment period will last 14 weeks, followed by a 1-week safety follow-up period.
- Status (registry)
- Withdrawn
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 16 Jun 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Type 2 diabetes, Chronic kidney disease
- NCT number
- NCT07786571
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of strong CYP3A4 inducers (e.g., rifampicin) or inhibitors (e.g., ketoconazole) that cannot be discontinued.
- Dialysis for acute renal failure within 3 months before run-in, current dialysis, or need for/planned kidney transplantation within 12 months.
- Use of corticosteroids or immunosuppressants within the past 6 months.
- Current use of incretin-based therapies.
Other illness
- Type 1 diabetes mellitus, latent autoimmune diabetes in adults (LADA), or other specific types of diabetes.
- Severe heart failure (NYHA class III-IV) or a history of acute coronary syndrome or stroke within the past 6 months.
- Malignancy or life expectancy <6 months.
- Known allergy to dorzagliatin or any of its components.
- Known allergy to linagliptin or any of its components.
- Mental illness or cognitive impairment preventing compliance with study follow-up.
- Severe gastrointestinal disease affecting drug absorption.
Lab values
- Active liver disease (ALT/AST >3 × ULN) or liver cirrhosis (Child-Pugh class B or above).
- Severe hypertriglyceridemia (>5.7 mmol/L).
Other
- Diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 3 months.
- Pregnant or lactating women, or women of childbearing potential not using effective contraception.
- Current participation in another interventional clinical trial.
Who the study is looking for
- Aged 18 to 80 years.
- Diagnosed with type 2 diabetes mellitus according to the 2026 American Diabetes Association (ADA) criteria or the 2024 Chinese Guidelines for the Prevention and Treatment of Diabetes.
- Diagnosed with chronic renal insufficiency, with eGFR <45 mL/min/1.73 m² calculated using the Modification of Diet in Renal Disease (MDRD) equation, and not receiving maintenance dialysis.
- HbA1c between 7.0% and 9.0%.
- Receiving a stable antihyperglycemic treatment regimen for at least 4 weeks prior to enrollment. The regimen should include basal insulin injection (excluding insulin-incretin combination preparations) and 0 to 2 oral antidiabetic drugs. Oral antidiabetic drugs are limited to metformin, SGLT2 inhibitors, alpha-glucosidase inhibitors, meglitinides, and TZDs.
- Written informed consent provided.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.